相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Does ponatinib cross the blood-brain barrier?
Muhammad B. Abid et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Current disease modifying approaches to treat Parkinson's disease
Dan Lindholm et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2016)
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Daniel J. Klionsky et al.
AUTOPHAGY (2016)
Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration
Saurav Brahmachari et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer
Timothy P. Heffron
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Synucleinopathies: past, present and future
M. G. Spillantini et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2016)
Nilotinib - Differentiating the Hope from the Hype
Richard K. Wyse et al.
JOURNAL OF PARKINSONS DISEASE (2016)
Nilotinib Effects in Parkinson's Disease and Dementia with Lewy Bodies
Fernando Pagan et al.
JOURNAL OF PARKINSONS DISEASE (2016)
The genetics of Parkinson's disease
Stephen Mullin et al.
BRITISH MEDICAL BULLETIN (2015)
NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. (vol 14, pg 795, 2015)
Chadwick W. Christine
LANCET NEUROLOGY (2015)
Basic Science Breaks Through: New Therapeutic Advances in Parkinson's Disease
Patrik Brundin et al.
MOVEMENT DISORDERS (2015)
Disease-Modifying Strategies for Parkinson's Disease
Lorraine V. Kalia et al.
MOVEMENT DISORDERS (2015)
NILOTINIB AND BOSUTINIB MODULATE PRE-PLAQUE ALTERATIONS OF BLOOD IMMUNE MARKERS AND NEURO-INFLAMMATION IN ALZHEIMER'S DISEASE MODELS
I. Lonskaya et al.
NEUROSCIENCE (2015)
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
Tanya Simuni et al.
LANCET NEUROLOGY (2015)
Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson's Disease
Iciar Aviles-Olmos et al.
JOURNAL OF PARKINSONS DISEASE (2014)
c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease
Anne-Laure Mahul-Mellier et al.
HUMAN MOLECULAR GENETICS (2014)
CDK5-mediated phosphorylation and autophagy of RKIP regulate neuronal death in Parkinson's disease
Zheng Wen et al.
NEUROBIOLOGY OF AGING (2014)
Parkin Plays a Role in Sporadic Parkinson's Disease
Ted M. Dawson et al.
NEURODEGENERATIVE DISEASES (2014)
A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson's disease
Akie Tanabe et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2014)
The c-Abl inhibitor, Nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease
Senthilkumar S. Karuppagounder et al.
SCIENTIFIC REPORTS (2014)
Diabetes drugs and neurological disorders: new views and therapeutic possibilities
Cesare Patrone et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of -synuclein in Parkinsons disease models
Michaeline L. Hebron et al.
HUMAN MOLECULAR GENETICS (2013)
Neuroprotective Efficacy of a New Brain-Penetrating C-Abl Inhibitor in a Murine Parkinson's Disease Model
Syed Z. Imam et al.
PLOS ONE (2013)
Dopamine signaling negatively regulates striatal phosphorylation of Cdk5 at tyrosine 15 in mice
Yukio Yamamura et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2013)
Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease
Giuseppa Mudo et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2012)
An update on dual Src/Abl inhibitors
Francesca Musumeci et al.
FUTURE MEDICINAL CHEMISTRY (2012)
The Parkinson disease protein α-synuclein inhibits autophagy
Ashley R. Winslow et al.
AUTOPHAGY (2011)
PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
Joo-Ho Shin et al.
CELL (2011)
Involvement of cyclin-dependent kinase-5 in the kainic acid-mediated degeneration of glutamatergic synapses in the rat hippocampus
Noora Putkonen et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2011)
c-Abl in Neurodegenerative Disease
Sarah D. Schlatterer et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2011)
Novel Regulation of Parkin Function through c-Abl-Mediated Tyrosine Phosphorylation: Implications for Parkinson's Disease
Syed Z. Imam et al.
JOURNAL OF NEUROSCIENCE (2011)
Discovery of 3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a Potent, Orally Active Pan-Inhibitor of Breakpoint Cluster Region-Abelson (BCR-ABL) Kinase Including the T315I Gatekeeper Mutant
Wei-Sheng Huang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Parkinson's Disease: 10 Years of Progress, 1997-2007
Stanley Fahn
MOVEMENT DISORDERS (2010)
Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function
Han Seok Ko et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Molecular biology of bcr-abl1-positive chronic myeloid leukemia
Alfonso Quintas-Cardama et al.
BLOOD (2009)
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells
L. L. Remsing Rix et al.
LEUKEMIA (2009)
What Causes Cell Death in Parkinson's Disease?
Amitabh Gupta et al.
ANNALS OF NEUROLOGY (2008)
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia
Kimmo Porkka et al.
BLOOD (2008)
Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis
Neil P. Shah et al.
CANCER CELL (2008)
2-aminothiazole as a novel kinase inhibitor template.: Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor
Jagabandhu Das et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
E. Weisberg et al.
BRITISH JOURNAL OF CANCER (2006)
ER stress and neurodegenerative diseases
D Lindholm et al.
CELL DEATH AND DIFFERENTIATION (2006)
Impaired degradation of mutant α-synuclein by chaperone-mediated autophagy
AM Cuervo et al.
SCIENCE (2004)
Regulation of the C-Abl and Bcr-Abl tyrosine kinases
O Hantschel et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease
PD Smith et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
α-synuclein locus triplication causes Parkinson's disease
AB Singleton et al.
SCIENCE (2003)
Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug
R Capdeville et al.
NATURE REVIEWS DRUG DISCOVERY (2002)
分享论文
